Finance

Lists
NVS:NYSE
Novartis AG
$159.85
+2.40%
(+3.74) 1D
$160.26
+0.26% (+0.41)
After hours
Closed: Jul 28, 4:00:02 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for NVS...
Open
$158.07
High
$160.34
Low
$158.02
Mkt. cap
327.32B
Avg. vol.
2.09M
Volume
1.69M
Dividend
2.97%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
24.14
52-wk high
$170.46
52-wk low
$112.34
EPS
$6.62
Beta
0.44
Shares outstanding
2.03B
No. of employees
75K
Open
$158.07
High
$160.34
Low
$158.02
Mkt. cap
327.32B
Avg. vol.
2.09M
Volume
1.69M
Dividend
2.97%
Quarterly dividend
$1.19
Ex-dividend date
Mar 10, 2026
P/E ratio
24.14
52-wk high
$170.46
52-wk low
$112.34
EPS
$6.62
Beta
0.44
Shares outstanding
2.03B
No. of employees
75K
News stories
From sources across the web
Profile
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Novartis manufactures the drugs clozapine, diclofenac, carbamazepine, valsartan, imatinib mesylate, cyclosporine, letrozole, methylphenidate, terbinafine, deferasirox, and others. Novartis was formed in 1996 by the merger of Ciba-Geigy and Sandoz. It was considered the largest corporate merger in history during that time. The pharmaceutical and agrochemical divisions of both companies formed Novartis as an independent entity. The name Novartis was based on the Latin terms, novae artes. After the merger, other Ciba-Geigy and Sandoz businesses were sold, or, like Ciba Specialty Chemicals, spun off as independent companies. The Sandoz brand disappeared for three years, but was revived in 2003 when Novartis consolidated its generic drugs businesses into a single subsidiary and named it Sandoz. Wikipedia
About Novartis AG
CEOVasant Narasimhan
Employees75.3K
FoundedFeb 29, 1996
HeadquartersBasel, Basel City, Switzerland
SectorPharmaceutical industry
Websitenovartis.com
Analyst ratings
Based on 5 analysts giving stock ratings to NVS in the past 3 months
Hold
Buy
2
Hold
2
Sell
1
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for NVS in the last 3 months.
Highest
Current $159.85
$180.00 (+12.61%)
Average
$156.50 (-2.10%)
Lowest
$139.00 (-13.04%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kerry Holford
Berenberg Bank
Hold
Maintained
$147.00
-8%
07/27/2026
Steve Scala
TD Cowen
Hold
Maintained
$180.00
+12.6%
07/27/2026
Unknown Analyst
Goldman Sachs
Sell
Maintained
$139.00
-13%
07/22/2026
Sachin Jain
Bank of America Securities
Buy
Maintained
-
-
07/21/2026
Jasper Hellweg
Argus Research
Buy
Reiterated
$160.00
+0.1%
06/04/2026
Thibault Boutherin
Morgan Stanley
Buy
Maintained
$170.00
+6.3%
03/26/2026
Justin Smith
Bernstein
Hold
Initiated
-
-
03/19/2026
David Toung
Argus Research
Buy
Upgraded
$180.00
+12.6%
03/11/2026
Last report
Jul 21, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$2.41 / $2.15
+12.21%beat
Revenue / Est. (USD)
14.95B / 14.06B
+6.36%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
14.36B
13.86B
13.52B
14.95B
Cost of goods sold
3.54B
3.54B
3.44B
3.68B
Cost of revenue
3.54B
3.54B
3.44B
3.68B
Research and development expenses
2.86B
2.84B
2.78B
2.74B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.30B
3.44B
3.14B
3.23B
Operating expense
6.24B
6.46B
5.96B
6.10B
Total operating expenses
9.77B
10.00B
9.40B
9.78B
Operating income
4.58B
3.86B
4.12B
5.18B
Other non operating income
-7.00M
-130.00M
4.00M
19.00M
EBT including unusual items
4.20B
3.22B
3.84B
4.27B
EBT excluding unusual items
4.29B
3.49B
3.78B
4.73B
Income tax expense
266.00M
814.00M
683.00M
1.01B
Effective tax rate
6.34%
25.30%
17.79%
23.71%
Other operating expenses
70.00M
190.00M
42.00M
127.00M
Net income
3.93B
2.41B
3.16B
3.26B
Net profit margin
27.36%
17.38%
23.34%
21.83%
Earnings per share
2.25
2.03
1.99
2.41
Interest and investment income
-
373.00M
-
-
Interest expense
-281.00M
-304.00M
-343.00M
-462.00M
Net interest expenses
-281.00M
69.00M
-343.00M
-462.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
5.78B
4.96B
5.24B
6.30B
Gain or loss from assets sale
81.00M
80.00M
-159.00M
-247.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer